首页> 外文OA文献 >Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation

【2h】

Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation

机译：Vorinostat的I / II试验与Rituximab，环磷酰胺，依托磷脂和泼尼松作为老年患者的复发或耐火弥漫性大型B细胞淋巴瘤的姑息治疗没有有资格进行自体干细胞移植

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
David J. Straus; Paul A. Hamlin; Matthew J. Matasar; Maria Lia Palomba; Pamela R. Drullinsky; Andrew D. Zelenetz; John F. Gerecitano; Ariela Noy; Audrey M. Hamilton; Rebecca Elstrom; Brett Wegner; Katy Wortman; David Cella;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation [J] . Straus David J., Hamlin Paul A., Matasar Matthew J., British Journal of Haematology . 2015,第5期

机译：伏立诺他用于利妥昔单抗，环磷酰胺，依托泊苷和强的松的姑息治疗的I / II期临床试验，用于老年复发性或难治性弥漫性大B细胞淋巴瘤不适合自体干细胞移植的老年患者
2. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone. [J] . Chen YB, Hochberg EP, Feng Y, Leukemia and lymphoma . 2010,第5期

机译：与未经环磷酰胺，阿霉素，长春新碱和泼尼松治疗失败的复发或难治性弥漫性大B细胞淋巴瘤复发或难治性弥漫性大B细胞淋巴瘤患者相比，最初的利妥昔单抗，环磷酰胺，阿霉素，长春新碱和泼尼松治疗失败的患者的特征和结果。
3. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi [J] . MerliF., LuminariS., RossiG., Leukemia and lymphoma . 2012,第4期

机译：环磷酰胺，阿霉素，长春新碱，泼尼松和利妥昔单抗与表柔比星，环磷酰胺，长春花碱，泼尼松和利妥昔单抗用于老年“适合”弥漫性大B细胞淋巴瘤患者的初始治疗：Intergruppo Italiano Linfomi的ANZINTER3试验结果
4. Mutational profile of Diffuse Large B-cell Lymphoma with central nervous system relapse: analysis of CBioPortal for Cancer Genomics database [C] . Elena Voropaeva, Olga Beresina, Tatyana Pospelova, Conference on Cognitive Sciences, Genomics and Bioinformatics . 2020

机译：弥漫性大B细胞淋巴瘤与中枢神经系统复发的突变特征：用于癌症基因组学数据库的CBioPortal分析
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Phase III Randomized Study of Rituximab/Carmustine Etoposide Cytarabine and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial [O] . Julie M. Vose, Shelly Carter, Linda J. Burns, -1

机译：利妥昔单抗/卡莫司汀依托泊苷阿糖胞苷和美法仑（BEAM）与碘131 Tositumomab / BEAM与自体造血细胞移植治疗复发性弥漫性大B细胞淋巴瘤的III期随机研究：来自BMT CTN 0401试验的结果
7. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial [O] . Luis Fayad, Stephen M. Ansell, Ranjana Advani, 2015

机译：DACETUZUMAB加里康妥昔单抗，IFOSFAMIDE，CARBOPLATIN和ETOPOSIDE作为弥漫性大型B细胞淋巴瘤患者的救助治疗，RITUXIMAB，环磷酰胺，多码霉素，长春碱和泼尼松酮：随机，双盲，安慰剂控制相2B试验

Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation

著录项

引文网络

相似文献

相关主题

期刊订阅